Tunç, MuratErbilen, Esin2021-06-232021-06-2320060002-9394https://doi.org/10.1016/j.ajo.2006.05.003https://hdl.handle.net/20.500.12491/5821PURPOSE: To determine the efficiency of topical cyclosporine,A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC). DESIGN: Interventional case reports. METHODS: Two patients who had positive margins following surgical excision of CCSC were treated by topical CSA (0.05%) four times a day for 12 weeks, and topical MMC (0.01%) four times a day was combined with CSA at the second, fourth, and sixth weeks of the treatment. We controlled the tumor recurrence, vision, and ocular surface healing during the follow-up. RESULTS: There was no tumor recurrence during the follow up of 18 months. Limbal vascularization regressed considerably and the vision improved without any ocular surface problems in both patients. CONCLUSIONS: As an adjunctive treatment, topical CSA (0.05%) combined with MMC (0.01%), may prevent tumor recurrence and provide excellent ocular surface healing in diffuse CCSC.eninfo:eu-repo/semantics/closedAccessCombinedMitomycin CConjunctivalCornealArticle10.1016/j.ajo.2006.05.0031424673675170118632-s2.0-33748980786Q1WOS:000241098900022Q1